Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurélie Bardet

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Clinical Trials (London, England)|September 21, 2019
Sequential or combined designs for Phase I/II clinical trials? A simulation studyCaroline Rossoni, Aurélie Bardet, Birgit Geoerger, et al.
British Journal of Haematology|December 13, 2017
A retrospective study on the management of patients with rituximab refractory follicular lymphomaPhilippe Solal-Céligny, Pierre Leconte, Aurélie Bardet, et al.
BMJ Open|June 29, 2026
Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI studyHermann Toplak, Joris J Komen, Aurélie Bardet, et al.
Frontiers in Cardiovascular Medicine|March 30, 2026
Lipid management in high cardiovascular risk patients in France: a comparison with rest of Europe patients from 1-year follow-up of SANTORINIJean Ferrières, Kausik K Ray, Alberico L Catapano, et al.
JAMA Network Open|December 2, 2022
Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug InteractionsElie Rassy, Aurélie Bardet, Omar Bougacha, et al.
Annals of Palliative Medicine|March 11, 2022
Development of a Decision-Aid Form (DAF) for the stratification of care in a French comprehensive cancer center, a tool to support identification of care goalsLaurence Vigouret-Viant, Clémence Legoupil, Aurélie Bardet, et al.
Journal of Telemedicine and Telecare|June 17, 2021
Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility studyCécile Charles, Aurélie Bardet, Nusaïbah Ibrahimi, et al.
Leukemia & Lymphoma|March 9, 2017
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE studyDriss Chaoui, Sylvain Choquet, Laurence Sanhes, et al.
European Journal of Preventive Cardiology|June 11, 2024
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI studyKausik K Ray, Carlos Aguiar, Marcello Arca, et al.
The Lancet. Oncology|July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trialPatricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Clinical Trials (London, England)|September 21, 2019
Sequential or combined designs for Phase I/II clinical trials? A simulation studyCaroline Rossoni, Aurélie Bardet, Birgit Geoerger, et al.
British Journal of Haematology|December 13, 2017
A retrospective study on the management of patients with rituximab refractory follicular lymphomaPhilippe Solal-Céligny, Pierre Leconte, Aurélie Bardet, et al.
BMJ Open|June 29, 2026
Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI studyHermann Toplak, Joris J Komen, Aurélie Bardet, et al.
Frontiers in Cardiovascular Medicine|March 30, 2026
Lipid management in high cardiovascular risk patients in France: a comparison with rest of Europe patients from 1-year follow-up of SANTORINIJean Ferrières, Kausik K Ray, Alberico L Catapano, et al.
JAMA Network Open|December 2, 2022
Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug InteractionsElie Rassy, Aurélie Bardet, Omar Bougacha, et al.
Annals of Palliative Medicine|March 11, 2022
Development of a Decision-Aid Form (DAF) for the stratification of care in a French comprehensive cancer center, a tool to support identification of care goalsLaurence Vigouret-Viant, Clémence Legoupil, Aurélie Bardet, et al.
Journal of Telemedicine and Telecare|June 17, 2021
Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility studyCécile Charles, Aurélie Bardet, Nusaïbah Ibrahimi, et al.
Leukemia & Lymphoma|March 9, 2017
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE studyDriss Chaoui, Sylvain Choquet, Laurence Sanhes, et al.
European Journal of Preventive Cardiology|June 11, 2024
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI studyKausik K Ray, Carlos Aguiar, Marcello Arca, et al.
The Lancet. Oncology|July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trialPatricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Pageof 2